Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

NCT01578239 is registered in ClinicalTrials.gov with Advanced Accelerator Applications as lead sponsor.

NCT NCT01578239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01578239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Lead sponsor
Advanced Accelerator Applications
Phase
Phase 3
Overall status
Completed
Start date
September 6, 2012
Completion date
January 18, 2021
Enrollment
231 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid tumor of the small bowel, neuroendocrine tumour